{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Efficacy Analyses', 'Section 5 Study', 'Figure 1 - Study 205678 Schematic', 'To account for possible', 'Design', 'revised to remove enrollment references', 'under/over enrollment.', 'Additional clarification that IA for futility', 'Clarification of ORR analysis at', 'is planned for ORR based on', 'IA and final analysis', \"investigator's assessment\", 'Clarification that lyophilized cohort will', 'be analyzed separately from participants', 'randomized to the frozen solution', 'Clarification that the final analysis of the', 'primary endpoint (ORR) will be', 'performed 6 months after the last', 'participant is randomized', 'Section 6.1 Inclusion', 'Changed e.g. to i.e. for the IMiD listed', 'The Latin abbreviation of e.g.', 'Criteria', 'under Inclusion criteria 4b', 'which translates to \"for example\"', 'and is commonly confused with', 'Section 1 Protocol', 'the Latin abbreviation of i.e.', 'Synopsis Inclusion', 'which translates to \"in other', 'Criteria', 'words\". The intent was that', 'participants need to be refractory', \"to the IMiD's lenalidomide or\", 'Pomalidomide ONLY (not', 'thalidomide) and therefore the', 'correct abbreviation is \"i.e.\"', 'Section 7 Treatments', 'Added Infusion Time', 'To address regulatory comments', 'Removed text to specify the lyophilized', 'cohort will be initiated when enrollment', 'has completed in the frozen arms', 'To more accurately reflect study', 'conduct', 'Section 9 Study', 'Table 14 Correction of FISH testing', 'Typographical error to align with', 'Assessments and', 'results', 'Section 7.3, method of treatment', 'Procedures', 'assignment', 'Section 9.11.3', 'Window added for patient interviews', 'Updated to align with Section 2,', 'Schedule of Activities', 'Qualitative Telephone', 'Interview (Patient', 'Interviews)', 'To reflect shortened enrolment', 'Section 10.1', 'Update the timing of final ORR analysis', '4']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name Description of Change', 'Brief Rationale', 'Hypothesis Testing', 'Clarification that lyophilized cohort will', 'period', 'be analyzed separately from participants', 'randomized to the frozen solution', 'Clarification of ORR analysis at', 'IA and final analysis', 'Section 10.2 Sample', 'Provide updated language on IA and', 'Size Determination', 'final analysis based on sample size of', 'To reflect actual enrollment onto', '100 participants per arm.', 'the frozen liquid solution arms of', 'the study', 'Section 10.3 Sample', 'Update Table 15 to include power', 'Size Sensitivity', 'scenarios for sample size of 100', 'To accommodate increase in', 'participants per arm.', 'sample size due to over', 'enrolment.', 'Section 10.4', 'Add a new analysis population', 'To evaluate the effect of over-', 'Populations for', '(Efficacy), which consist of the first 130', 'enrollment with respect to the', 'Analysis', 'randomized patients', 'original planned sample size for', 'primary and key secondary', 'endpoints.', 'Section 10.5.1', 'Clarifying the analysis population for', 'Efficacy Analyses', 'efficacy endpoints at Final analysis', 'To accommodate increase in', 'sample size due to over', 'enrolment.', 'Clarification that IA for futility is planned', \"for ORR based on investigator's\", 'assessment.', 'ORR based on IRC assessment', 'is planned for the final primary', 'analysis and the IA will be', 'performed based on investigator', 'assessment.', 'Section 10.5.9 Interim', 'Provide updated language on stopping', 'Analyses', 'rule/boundary crossing probability for IA', 'To accommodate increase in', 'and final analysis based on sample size', 'sample size due to over', 'of 100 participants per arm.', 'enrolment.', '5']['2017N330177_04', 'CONFIDENTIAL', '205678', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '3', '1. SYNOPSIS', '11', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '20', '3.', 'INTRODUCTION', '33', '3.1.', 'Study Rationale', '33', '3.2.', 'Background - BCMA and Multiple Myeloma', '34', '3.3.', 'Antibody-Drug Conjugate GSK2857916', '34', '3.4.', 'Human Experience with GSK2857916', '35', '3.4.1.', 'Thrombocytopenia', '36', '3.4.2.', 'Corneal Events', '36', '3.4.3.', 'Pharmacokinetics', '37', '3.4.4.', 'Clinical Activity', '37', '3.5.', 'Benefit / Risk Assessment', '38', '3.5.1.', 'Risk Assessment', '38', '3.5.2.', 'Benefit Assessment', '40', '3.5.3.', 'Overall Benefit-Risk Conclusions', '41', '4.', 'OBJECTIVES AND ENDPOINTS', '41', '5.', 'STUDY DESIGN', '43', '5.1.', 'Overall Design', '43', '5.2.', 'Number of Participants', '46', '5.3.', 'Participant and Study Completion', '47', '5.4.', 'Scientific Rationale for Study Design', '47', '5.5.', 'Dose Justification', '48', '6.', 'STUDY POPULATION', '51', '6.1.', 'Inclusion Criteria', '51', '6.2.', 'Exclusion Criteria', '54', '6.3.', 'Lifestyle Restrictions', '55', '6.4.', 'Screen Failures', '55', '7.', 'TREATMENTS', '56', '7.1.', 'GSK2857916 Treatments Administered', '56', '7.2.', 'Dose Modification', '57', '7.2.1.', 'Adjustments Due to Body Weight', '57', '7.2.2.', 'Dose Reductions for Toxicity', '57', '7.2.3.', 'Corneal Supportive Care Guidelines', '62', '7.3.', 'Method of Treatment Assignment', '62', '7.4.', 'Blinding', '63', '7.5.', 'reparation/Handling/Storage/Accountability', '63', '7.6.', 'Treatment Compliance', '64', '7.7.', 'Concomitant Therapy', '64', '7.7.1.', 'Permitted Medication(s)', '65', '7.7.2.', 'Prohibited Medication(s', '65', '7.7.3.', 'Prohibited Device(s)', '65', '6']\n\n###\n\n", "completion": "END"}